Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genky DrugStores Co., Ltd. ( (JP:9267) ) just unveiled an announcement.
Genky DrugStores reported solid results for the six months ended December 20, 2025, with net sales rising 10.6% year on year to ¥109.3 billion and net income attributable to owners of the parent increasing 23.0% to ¥4.0 billion, reflecting improved profitability and higher operating leverage. Total assets and equity also grew, pushing the equity ratio up to 42.8%, while the company maintained its dividend plan of ¥13.00 per share for the full fiscal year and left its full-year forecast unchanged, targeting 10.2% growth in net sales and an 11.1% rise in net income, signaling confidence in continued expansion for shareholders and other stakeholders.
The most recent analyst rating on (JP:9267) stock is a Buy with a Yen4934.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.
More about Genky DrugStores Co., Ltd.
Genky DrugStores Co., Ltd. is a Japan-based drugstore operator listed on the Tokyo Stock Exchange that sells pharmaceuticals, daily necessities, and related products through its retail network. The company focuses on expanding sales in the domestic drugstore market, leveraging a low-cost, everyday-value format to drive steady growth in regional communities.
Average Trading Volume: 95,093
Technical Sentiment Signal: Buy
Current Market Cap: Yen138.2B
See more insights into 9267 stock on TipRanks’ Stock Analysis page.